SCHEMBL5845937

SCHEMBL5845937

CCc1nc(C2CCC(C(C)(C)C)CC2)n2nc(-c3cccc(Br)c3)[nH]c(=O)c12

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 8/20 0.42
PDE1A P54750 4/20 0.39
PDE1B Q01064 4/20 0.39
PDE1C Q14123 4/20 0.39
BRD4 O60885 3/20 0.36
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
NPC1 O15118 1/20 0.32
POLB P06746 1/20 0.32
RAB9A P51151 1/20 0.32
TYMP P19971 1/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PARP1 P09874 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5859599 1.00 PDE5A (0.42) PDE5APDE1APDE1BPDE1CBRD4
SCHEMBL5884154 0.90 PDE5A (0.50) PDE5APDE1APDE1BPDE1CBRD4
SCHEMBL5884369 0.90 PDE5A (0.48) PDE5APDE1APDE1BPDE1CBRD4
SCHEMBL5845215 0.89 PDE5A (0.42) PDE5APDE1APDE1BPDE1CHDAC1
SCHEMBL5845892 0.89 PDE5A (0.42) PDE5APDE1APDE1BPDE1CHDAC1
SCHEMBL5860664 0.89 PDE5A (0.42) PDE5APDE1APDE1BPDE1CHDAC1
SCHEMBL5860660 0.89 PDE5A (0.42) PDE5APDE1APDE1BPDE1CHDAC1
SCHEMBL5860641 0.89 PDE5A (0.42) PDE5APDE1APDE1BPDE1CHDAC1
SCHEMBL5845859 0.89 PDE5A (0.44) PDE5APDE1APDE1BPDE1CPOLB
SCHEMBL5845866 0.89 PDE5A (0.44) PDE5APDE1APDE1BPDE1CPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115602-B2 Heterocycles 3 BAYER AKTIENGESELLSCHAFT (DE) 2006-10-03 US disclosed
US-7074790-B2 5-ethylimidarotriazones BAYER HEALTHCARE AG (DE) 2006-07-11 US disclosed
US-20060040942-A1 5-ethylimidarotriazones BAYER HEALTHCARE AG (DE) 2006-02-23 US disclosed
US-20050065153-A1 Novel heterocycles 3 BAYER AKTIENGESELLSCHAFT (DE) 2005-03-24 US disclosed
EP-1506198-A1 5-ETHYLIMIDAROTRIAZONES Bayer HealthCare AG (DE) 2005-02-16 EP disclosed
EP-1399447-A1 IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES Bayer HealthCare AG (DE) 2004-03-24 EP disclosed
WO-2003097645-A1 5-ETHYLIMIDAROTRIAZONES BAYER HEALTHCARE AG (DE) 2003-11-27 WO disclosed
US-20030139415-A1 Novel heterocycles 3 BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) 2003-07-24 US disclosed
WO-2002098879-A1 IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES BAYER HEALTHCARE AG (DE) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139415-A1 Novel heterocycles 3 NFATC1, NOD2, NFKBIA PDE5A 1993/4885PDE1A 3380/4885PDE1B 3869/4885
US-20060040942-A1 5-ethylimidarotriazones IL5, EPX, NFATC1 PDE5A 378/4885PDE1A 834/4885PDE1B 1074/4885
US-20050065153-A1 Novel heterocycles 3 NFATC1, NOD2, NFKBIA PDE5A 1993/4885PDE1A 3380/4885PDE1B 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.